Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, highlighting a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential increase from the fourth quarter of 2025. The company attributed the growth to new account activation and deeper utilization within existing sites, signaling that Nociscan is becoming increasingly integrated into clinical workflows for chronic low back pain management.
The company noted that approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies like Nociscan that provide objective evaluation of discogenic pain. Aclarion's CEO Brent Ness stated, "Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US."
Reimbursement progress has been a key catalyst, with Nociscan now covered by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. The company also launched a targeted direct-to-patient campaign in the U.K., including a video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage with payers through its Nociscan Reimbursement Program to establish coverage pathways.
On the clinical front, the CLARITY randomized trial is ongoing, with a preliminary internal readout expected in the second half of 2026 and public disclosure of early interim results anticipated in late 2026. Seven clinical trials and multiple investigator-initiated real-world evidence studies are underway to support reimbursement discussions and potential local coverage decisions by commercial insurers.
Aclarion also strengthened its intellectual property portfolio with a new patent covering the use of AI in workflows of future products. The company now holds 64 issued and pending patents worldwide, reinforcing its competitive position. Financially, Aclarion reported $19.0 million in cash as of March 31, 2026, with no debt and a clean capital structure. The company announced a $2.5 million share repurchase program and believes its cash runway extends into the second half of 2027 based on current operating plans.
For more information, visit the company's newsroom at https://tinyurl.com/aconnewsroom and the Nociscan site map at https://www.aclarion.com.
